Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up
- PMID: 8578851
- DOI: 10.1016/0264-410x(95)00064-8
Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up
Abstract
A two-dose vaccination program against measles, mumps, and rubella (MMR) viruses was started in Finland in 1982. In this program the trivalent MMR-II vaccine (MSD, USA) was offered to children at the ages of 14-18 months and 6 years followed by revaccination 4-5 years later. The vaccination coverage has been high (97%) and MMR infections have practically been eliminated in the Finnish population. In a serological follow-up program sequential serum samples were obtained from 254 children (127 14-18-month-old vaccinees and 127 6-year-old vaccinees) during a 9-year follow-up period. Anti-mumps virus antibody titers were determined by enzyme immunoassay using purified whole mumps viruses as the antigen. In seronegative (n = 120) 14-18-month-old vaccinees the seroconversion rate was 86% (geometric mean titer 1/1670 +/- 1/270). The antibody levels fell rapidly (significance p < 0.01) within the first year of follow-up (mean titer 1/1080 +/- 1/190), but remained relatively stable in subsequent years. After revaccination the seropositivity rate was 95% (mean titer 1/2310 +/- 1/260) and declined more slowly thereafter to 86% (mean titer 1/1510 +/- 1/210) at year 9 of follow-up. The mean antibody titer was significantly (p < 0.05) higher 4 years after the second MMR vaccination when compared with the corresponding time point after the first vaccination. In 6-year-old seronegative vaccinees the increase and decay of anti-mumps virus antibodies after the first MMR vaccination was similar to that seen in the group of younger vaccinees. A two-dose MMR vaccination protocol resulted in a high mumps immunity level in the vaccinated population.
Similar articles
-
Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.Vaccine. 2000 Jul 15;18(27):3106-12. doi: 10.1016/s0264-410x(00)00139-0. Vaccine. 2000. PMID: 10856790
-
Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.Vaccine. 1995 Nov;13(16):1611-6. doi: 10.1016/0264-410x(95)00098-l. Vaccine. 1995. PMID: 8578850
-
Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.Vaccine. 2000 Jan 31;18(14):1382-92. doi: 10.1016/s0264-410x(99)00397-7. Vaccine. 2000. PMID: 10618536 Clinical Trial.
-
[Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].Ugeskr Laeger. 1992 Jul 13;154(29):2008-13. Ugeskr Laeger. 1992. PMID: 1509566 Review. Danish.
-
Rational use of measles, mumps and rubella (MMR) vaccine.Drugs. 1993 May;45(5):677-83. doi: 10.2165/00003495-199345050-00005. Drugs. 1993. PMID: 7686463 Review.
Cited by
-
Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice.J Virol. 2022 Apr 27;96(8):e0198321. doi: 10.1128/jvi.01983-21. Epub 2022 Apr 7. J Virol. 2022. PMID: 35389265 Free PMC article.
-
Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.Clin Immunol. 2022 Jan;234:108912. doi: 10.1016/j.clim.2021.108912. Epub 2021 Dec 28. Clin Immunol. 2022. PMID: 34968746 Free PMC article.
-
Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine.Int J Environ Res Public Health. 2020 Mar 5;17(5):1686. doi: 10.3390/ijerph17051686. Int J Environ Res Public Health. 2020. PMID: 32150969 Free PMC article. Review.
-
Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.Clin Microbiol Rev. 2020 Feb 26;33(2):e00151-19. doi: 10.1128/CMR.00151-19. Print 2020 Mar 18. Clin Microbiol Rev. 2020. PMID: 32102901 Free PMC article. Review.
-
Guidelines for the Prevention and Control of Mumps Outbreaks in Canada.Can Commun Dis Rep. 2010 Jan 4;36(Suppl 1):1-46. doi: 10.14745/ccdr.v36i00as1. eCollection 2010 Jan 4. Can Commun Dis Rep. 2010. PMID: 31680695 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources